XJPX4883
Market cap19mUSD
Dec 30, Last price
102.00JPY
1D
0.00%
1Q
3.03%
IPO
-95.36%
Name
Modalis Therapeutics Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
214.16%
Revenues
0k
-100.00%
Net income
-2.39b
L-11.50%
CFO
-2.25b
L+18.92%
Profile
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to control gene expressions through modulating the switch (epigenetics of a specific locus. The company has a. joint research agreement with JCR Pharmaceuticals Co., Ltd. to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was founded in 2016 and is headquartered in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 40,500 3,581.82% | ||||
Cost of revenue | 2,371,396 | 2,227,369 | |||
Unusual Expense (Income) | |||||
NOPBT | (2,371,396) | (2,186,869) | |||
NOPBT Margin | |||||
Operating Taxes | 1,213 | (4,321) | |||
Tax Rate | |||||
NOPAT | (2,372,609) | (2,182,548) | |||
Net income | (2,391,821) -11.50% | (2,702,709) 265.75% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 736,119 | 60,905 | |||
BB yield | |||||
| Debt | |||||
Debt current | |||||
Long-term debt | 412,500 | ||||
Deferred revenue | |||||
Other long-term liabilities | 34,900 | (45,084) | |||
Net debt | (1,539,937) | (3,001,162) | |||
| Cash flow | |||||
Cash from operating activities | (2,254,466) | (1,895,773) | |||
CAPEX | (39,699) | (197,287) | |||
Cash from investing activities | (39,699) | (185,719) | |||
Cash from financing activities | 1,216,451 | 63,683 | |||
FCF | (2,372,609) | (1,958,764) | |||
| Balance | |||||
Cash | 1,883,437 | 2,933,162 | |||
Long term investments | 69,000 | 68,000 | |||
Excess cash | 1,952,437 | 2,999,137 | |||
Stockholders' equity | (1,158,868) | (476,579) | |||
Invested Capital | 2,986,692 | 3,359,615 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 30,966 | 29,107 | |||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | (2,370,665) | (2,063,194) | |||
EV/EBITDA | |||||
Interest | 4,414 | 4,823 | |||
Interest/NOPBT | |||||